The endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathy.
Authors
J. Lambers
de Zeeuw D
Coll B
Andress D
Brennan JJ
Tang H
Houser M
Correa-Rotter R
Kohan D
Makino H
Pritchett Y
Remuzzi G
Tobe SW
Toto R
Viberti G
Parving HH
Perkovic Vlado
Type of Publication
Journal Article
Journal
Journal of the American Society of Nephrology
